Kennedy seeks faster health wins as White House pivots from vaccine fight

Robert F. Kennedy Jr. is being steered toward faster, more politically marketable health wins after his vaccine overhaul ran into a federal judge, as the White House looks for initiatives that can be sold to voters before the November midterm elections.

The shift follows a March 16 ruling that blocked key parts of Kennedy’s effort to reshape childhood vaccine policy, including a reduced immunization schedule and a reconstituted Centers for Disease Control and Prevention vaccine advisory panel. The court also paused a CDC change that had cut routine childhood vaccine recommendations from 17 diseases to 11, underlining how far Kennedy had tried to move the system and how quickly the effort met resistance.

Now the administration is leaning on narrower moves that fit Kennedy’s broader health brand. One of the clearest examples came when Donald Trump signed an executive order accelerating research and access to psychedelic drugs for serious mental illness. The White House said compounds including ibogaine could help patients whose conditions persist after standard therapy, especially veterans and people with treatment-resistant illness. That gives the administration an emotionally resonant story line, but the immediate beneficiaries remain a limited group, not the broader public health system Kennedy has said he wants to transform.

Another quick win came on April 23, when the Food and Drug Administration approved Otarmeni, or lunsotogene parvec-cwha, the first dual adeno-associated virus gene therapy for severe-to-profound and profound sensorineural hearing loss tied to biallelic OTOF variants. The treatment was cleared through the FDA’s National Priority Voucher Program. It offers a real medical advance for patients with that rare genetic condition, but its reach is narrow, touching a small pediatric and adult population rather than the millions affected by more common hearing loss.

Senior administration officials are also weighing food-policy steps and other treatments for childhood diseases that could be approved quickly, a sign that the White House wants visible health actions that can be announced on a short timeline. Trump is also eager to highlight prescription-drug price cuts attributed to his appointees, a reminder that the administration sees public health as a pocketbook issue as much as a medical one.

On April 24, HHS said the FDA would accelerate action on treatments for serious mental illness following the psychedelic order, reinforcing the scramble for tangible announcements. The political calculation is clear: deliver a series of popular, saleable health moves fast enough to blunt the backlash over vaccines, while keeping both vaccine-skeptical Trump voters and more mainstream voters inside the tent.